Skip to main content
main-content

The independent medical news service

Prostate cancer

07-08-2020 | Oncology | News | Article

Neoadjuvant chemohormonal therapy not yet encouraged for localized prostate cancer

The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.

31-07-2020 | Oncology | Highlight | Article

Cancer diagnostic delays due to COVID-19 may lead to high excess mortality

Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.

29-07-2020 | Oncology | News | Article

ADT tied to reduced COVID-19 severity

Receipt of androgen deprivation therapy may be associated with less severe COVID-19 outcomes, suggest data from New York City.

17-07-2020 | Oncology | News | Article

HSD3B1 variant shows minimal added value as treatment biomarker in mCRPC

The HSD3B1 CC pathogenic variant does not add prognostic information to standard clinical variables for men receiving abiraterone or enzalutamide for metastatic castration-resistant prostate cancer, study findings indicate.

03-07-2020 | Oncology | News | Article

Updated ESMO prostate cancer guidelines released

Click through for more information on these Clinical Practice Guidelines

03-07-2020 | Oncology | News | Article

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

24-06-2020 | Oncology | News | Article

Antiandrogen therapy boosts nonmetastatic CRPC survival

Adding an androgen receptor inhibitor to androgen deprivation therapy significantly improves the overall survival of men with nonmetastatic castration-resistant prostate cancer, according to results from three trials.

11-06-2020 | Oncology | News | Article

CONDOR: 18F-DCFPyL PET diagnoses biochemically recurrent prostate cancer

Positron-emission tomography using the novel prostate-specific membrane antigen targeted 18F-DCFPyL tracer shows “excellent diagnostic performance” in men with biochemically recurrent prostate cancer, researchers report.

02-06-2020 | Oncology | News | Article

Relugolix may offer better testosterone suppression than leuprolide

Men with advanced prostate cancer who receive the gonadotropin-releasing hormone antagonist relugolix are more likely to have sustained suppression of testosterone than those treated with leuprolide acetate, HERO trial data show.

29-05-2020 | Oncology | News | Article

FDA approves rucaparib, olaparib for mutated metastatic CRPC

Read more on these decisions

27-05-2020 | Oncology | News | Article

Data question ADT omission when using EBRT plus brachytherapy boost

Adding androgen deprivation therapy to external beam radiotherapy may result in better survival than adding a brachytherapy boost in men with intermediate- and high-risk prostate cancer, network meta-analysis data suggest.

22-05-2020 | Oncology | News | Article

Data reinforce HSD3B1 variant link to poor mCRPC outcome

Men with metastatic castration-resistant prostate cancer (mCRPC) who carry the CC genotype of the HSD3B1 c.1245A>C variant have worse responses to first-line abiraterone and enzalutamide than those with an AA or AC genotype, research shows.

13-05-2020 | Oncology | News | Article

EMA supports hybrid cabazitaxel formulation for mCRPC

Click here to read more

07-05-2020 | Oncology | News | Article

Link between ADT and reduced COVID-19 risk proposed

An analysis of Italian patients suggests a potential protective role of androgen deprivation therapy against SARS-CoV-2 infection.

28-04-2020 | Oncology | News | Article

IMbassador250: Atezolizumab–enzalutamide strikes out in mCRPC

The phase 3 IMbassador250 trial has failed to show any significant improvement in metastatic castration-resistant prostate cancer outcomes with the addition of atezolizumab to enzalutamide.

02-04-2020 | Oncology | News | Article

SABR benefits men with oligometastatic prostate cancer

Stereotactic ablative radiotherapy is associated with a significantly lower risk for disease progression at 6 months relative to observation in men with oligometastatic prostate cancer, phase 2 study data show.

13-03-2020 | Oncology | News | Article

Genetic link to poorer outcomes in men with low-volume metastatic CSPC

Prospective data now confirm that White men with low-volume metastatic castration-sensitive prostate cancer who have the adrenal-permissive HSD3B1 genotype have poorer outcomes than those with the adrenal-restrictive genotype.

09-03-2020 | Oncology | News | Article

Predictive prostate cancer models may identify potential candidates for active surveillance

US researchers have developed predictive models that could help identify men with prostate cancer who are likely to undergo pathologic downgrading after radical prostatectomy and therefore may be suitable candidates for active surveillance.

05-03-2020 | Oncology | News | Article

Combining MRI-targeted, systematic biopsy best for prostate cancer diagnosis

A combined approach using both MRI-targeted and systematic biopsy provides improved diagnostic accuracy for the detection of prostate cancer versus either strategy alone, say the Trio researchers.

26-02-2020 | Oncology | News | Article

Pembrolizumab–enzalutamide combination has ‘modest activity’ in mCRPC

The addition of pembrolizumab to enzalutamide has “modest activity” against metastatic castration-resistant prostate cancer that has become resistant to enzalutamide, say the KEYNOTE-199 researchers.

Image Credits